Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties

Journal of Clinical Investigation

Volumn 124, Issue 3, 2014, Pages 1199-1213

  Demeule, Michel ^a   Beaudet, Nicolas ^b   Régina, Anthony ^a   Besserer Offroy, Élie ^b   Murza, Alexandre ^b   Tétreault, Pascal ^b   Belleville, Karine ^b   Ché, Christian ^a   Larocque, Alain ^a   Thiot, Carine ^a   Béliveau, Richard ^c   Longpré, Jean Michel ^b   Marsault, Éric ^b   Leduc, Richard ^b   Lachowicz, Jean E ^a   Gonias, Steven L ^d   Castaigne, Jean Paul ^a   Sarret, Philippe ^b  

^a ANGIOCHEM INC   (Canada)

^b UNIVERSITY OF SHERBROOKE   (Canada)

^c UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANG 2002; ANGIOPEP 2; BUPRENORPHINE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MORPHINE; NEUROTENSIN; PEPTIDE; UNCLASSIFIED DRUG;

ANALGESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; BIOLOGICAL ACTIVITY; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; BLOOD BRAIN BARRIER; BLOOD PRESSURE; BODY TEMPERATURE; BONE CANCER; BRAIN CAPILLARY; BRAIN PERFUSION; BRAIN TISSUE; CANCER PAIN; CHRONIC CONSTRICTION INJURY; CHRONIC PAIN; COMPARATIVE STUDY; CONJUGATE; CONJUGATION; CONTROLLED STUDY; DRUG DEGRADATION; DRUG EFFICACY; DRUG PURIFICATION; ENDOCYTOSIS; EXPERIMENTAL SCIATIC NERVE INJURY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MEAN ARTERIAL PRESSURE; MOUSE; NEUROPATHIC PAIN; NONHUMAN; PAIN THRESHOLD; PARENCHYMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; RECEPTOR BINDING; REVERSED PHASE LIQUID CHROMATOGRAPHY; THERMAL STIMULATION; TIME OF FLIGHT MASS SPECTROMETRY; TRANSCYTOSIS; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ANALGESICS; ANIMALS; BLOOD-BRAIN BARRIER; BONE NEOPLASMS; CAPILLARY PERMEABILITY; CELL LINE; CELL LINE, TUMOR; CHRONIC PAIN; DRUG EVALUATION, PRECLINICAL; FORMALDEHYDE; INHIBITORY CONCENTRATION 50; MALE; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NEURALGIA; NOCICEPTION; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; SUCCINIMIDES;

EID: 84896765625     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI70647     Document Type: Article

References (91)

1. Daneman R. The blood-brain barrier in health and disease. Ann Neurol. 2012;72(5):648-672.
2. Cecchelli R, et al. Modelling of the blood-brain barrier in drug discovery and development. Nat Rev Drug Discov. 2007;6(8):650-661.
3. Pardridge WM. Blood-brain barrier delivery. Drug Discov Today. 2007;12(1-2):54-61.
4. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005;2(1):3-14.
5. Pardridge WM. Drug transport across the bloodbrain barrier. J Cereb Blood Flow Metab. 2012; 32(11):1959-1972.
6. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis. 2010;37(1):48-57.
7. Demeule M, et al. Identification and design of peptides as a new drug delivery system for the brain. J Pharmacol Exp Ther. 2008;324(3):1064-1072.
8. Mahley RW, Huang Y. Atherogenic remnant lipoproteins: role for proteoglycans in trapping, transferring, and internalizing. J Clin Invest. 2007; 117(1):94-98.
9. Strickland DK, Ashcom JD, Williams S, Burgess WH, Migliorini M, Argraves WS. Sequence identity between the alpha 2-macroglobulin receptor and low density lipoprotein receptor-related protein suggests that this molecule is a multifunctional receptor. J Biol Chem. 1990;265(29):17401-17404.
10. Lillis AP, Van Duyn LB, Murphy-Ullrich JE, Strickland DK. LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev. 2008;88(3):887-918.
11. Bertrand Y, et al. Transport characteristics of a novel peptide platform for CNS therapeutics. J Cell Mol Med. 2010;14(12):2827-2839.
12. Demeule M, et al. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. J Neurochem. 2008;106(4):1534-1544.
13. Che C, et al. New Angiopep-modified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration. J Med Chem. 2010;53(7):2814-2824.
14. Regina A, et al. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br J Pharmacol. 2008; 155(2):185-197.
15. Thomas FC, et al. Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharm Res. 2009;26(11):2486-2494.
16. Bertrand Y, et al. Influence of glioma tumour microenvironment on the transport of ANG1005 via low-density lipoprotein receptor-related protein 1. Br J Cancer. 2011;105(11):1697-1707
17. Kurzrock R, et al. Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. Mol Cancer Ther. 2012;11(2):308-316.
18. Drappatz J, et al. Phase I study of GRN1005 in recurrent malignant glioma. Clin Cancer Res. 2013; 19(6):1567-1576.
19. Kissin I. The development of new analgesics over the past 50 years: a lack of real breakthrough drugs. Anesth Analg. 2010;110(3):780-789.
20. Woolf CJ. Overcoming obstacles to developing new analgesics. Nat Med. 2010;16(11):1241-1247.
21. Gupta A, Mehdi A, Duwell M, Sinha A. Evidencebased review of the pharmacoeconomics related to the management of chronic nonmalignant pain. J Pain Palliat Care Pharmacother. 2010;24(2):152-156.
22. Boules M, Li Z, Smith K, Fredrickson P, Richelson E. Diverse roles of neurotensin agonists in the central nervous system. Front Endocrinol (Lausanne). 2013; 4:36.
23. Dobner PR. Neurotensin and pain modulation. Peptides. 2006;27(10):2405-2414.
24. Kleczkowska P, Lipkowski AW. Neurotensin and neurotensin receptors: characteristic, structureactivity relationship and pain modulation - a review. Eur J Pharmacol. 2013;716(1-3):54-60.
25. Sarret P, Beaudet A. Neurotensin receptors in the central nervous system. Handbook of Chemical Neuroanatomy. Vol. 61. Peptide Receptors, Part II. Amsterdam, the Netherlands: Elsevier; 2003:323-400
26. al-Rodhan NR, et al. Structure-antinociceptive activity of neurotensin and some novel analogues in the periaqueductal gray region of the brainstem. Brain Res. 1991;557(1-2):227-235.
27. Clineschmidt BV, McGuffin JC, Bunting PB. Neurotensin: antinocisponsive action in rodents. Eur J Pharmacol. 1979;54(1-2):129-139.
28. Nemeroff CB, et al. Alterations in nociception and body temperature after intracisternal administration of neurotensin, beta-endorphin, other endogenous peptides, and morphine. Proc Natl Acad Sci U S A. 1979;76(10):5368-5371.
29. Osbahr AJ, et al. Neurotensin-induced antinociception in mice: antagonism by thyrotropin-releasing hormone. J Pharmacol Exp Ther. 1981;217(3):645-651.
30. Roussy G, et al. Altered morphine-induced analgesia in neurotensin type 1 receptor null mice. Neuroscience. 2010;170(4):1286-1294.
31. Boules M, Johnston H, Tozy J, Smith K, Li Z, Richelson E. Analgesic synergy of neurotensin receptor subtype 2 agonist NT79 and morphine. Behav Pharmacol. 2011;22(5-6):573-581.
32. Boules M, Shaw A, Liang Y, Barbut D, Richelson E. NT69L, a novel analgesic, shows synergy with morphine. Brain Res. 2009;1294:22-28.
33. Kleczkowska P, et al. PK20, a new opioid-neurotensin hybrid peptide that exhibits central and peripheral antinociceptive effects. Mol Pain. 2010;6:86.
34. Willnow TE, Herz J. Genetic deficiency in low density lipoprotein receptor-related protein confers cellular resistance to Pseudomonas exotoxin A. Evidence that this protein is required for uptake and degradation of multiple ligands. J Cell Sci. 1994; 107(pt 3):719-726.
35. Mikhailenko I, et al. Recognition of α 2-macroglobulin by the low density lipoprotein receptorrelated protein requires the cooperation of two ligand binding cluster regions. J Biol Chem. 2001; 276(42):39484-39491.
36. Willnow TE, Orth K, Herz J. Molecular dissection of ligand binding sites on the low density lipoprotein receptor-related protein. J Biol Chem. 1994; 269(22):15827-15832.
37. Neels JG, van Den Berg BM, Lookene A, Olivecrona G, Pannekoek H, van Zonneveld AJ. The second and fourth cluster of class A cysteine-rich repeats of the low density lipoprotein receptor-related protein share ligand-binding properties. J Biol Chem. 1999; 274(44):31305-31311.
38. Fernandez-Castaneda A, et al. Identification of the low density lipoprotein (LDL) receptor-related protein-1 interactome in central nervous system myelin suggests a role in the clearance of necrotic cell debris. J Biol Chem. 2013;288(7):4538-4548.
39. Gully D, et al. Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist. J Pharmacol Exp Ther. 1997; 280(2):802-812.
40. Sarret P, Esdaile MJ, Perron A, Martinez J, Stroh T, Beaudet A. Potent spinal analgesia elicited through stimulation of NTS2 neurotensin receptors. J Neurosci. 2005;25(36):8188-8196.
41. Lafrance M, et al. Involvement of NTS2 receptors in stress-induced analgesia. Neuroscience. 2010; 166(2):639-652.
42. Tjolsen A, Berge OG, Hunskaar S, Rosland JH, Hole K. The formalin test: an evaluation of the method. Pain. 1992;51(1):5-17.
43. Sawynok J. The formalin test: characteristics and usefulness of the model. Reviews in Analgesia. 2004; 7:145-163.
44. Dore-Savard L, Beaudet N, Tremblay L, Xiao Y, Lepage M, Sarret P. A micro-imaging study linking bone cancer pain with tumor growth and bone resorption in a rat model. Clin Exp Metastasis. 2013; 30(2):225-236.
45. Dore-Savard L, et al. Behavioral, medical imaging and histopathological features of a new rat model of bone cancer pain. PLoS One. 2010;5(10):e13774.
46. Popp E, Schneider A, Vogel P, Teschendorf P, Bottiger BW. Time course of the hypothermic response to continuously administered neurotensin. Neuropeptides. 2007;41(5):349-354.
47. St-Gelais F, Jomphe C, Trudeau LE. The role of neurotensin in central nervous system pathophysiology: what is the evidence? J Psychiatry Neurosci. 2006; 31(4):229-245.
48. Gabathuler R. Blood-brain barrier transport of drugs for the treatment of brain diseases. CNS Neurol Disord Drug Targets. 2009;8(3):195-1204.
49. McGonigle P. Peptide therapeutics for CNS indications. Biochem Pharmacol. 2012;83(5):559-566.
50. Gabathuler R. Development of new peptide vectors for the transport of therapeutic across the bloodbrain barrier. Ther Deliv. 2010;1(4):571-586.
51. Pardridge WM. Biopharmaceutical drug targeting to the brain. J Drug Target. 2010;18(3):157-167.
52. Sarret P, Perron A, Stroh T, Beaudet A. Immunohistochemical distribution of NTS2 neurotensin receptors in the rat central nervous system. J Comp Neurol. 2003;461(4):520-538.
53. Moyse E, et al. Distribution of neurotensin binding sites in rat brain: a light microscopic radioautographic study using monoiodo [125I]Tyr3-neurotensin. Neuroscience. 1987;22(2):525-536.
54. Boudin H, Pelaprat D, Rostene W, Beaudet A. Cellular distribution of neurotensin receptors in rat brain: immunohistochemical study using an antipeptide antibody against the cloned high affinity receptor. J Comp Neurol. 1996;373(1):76-89.
55. Sarret P, Beaudet A, Vincent JP, Mazella J. Regional and cellular distribution of low affinity neurotensin receptor mRNA in adult and developing mouse brain. J Comp Neurol. 1998;394(3):344-356.
56. Alexander MJ, Leeman SE. Widespread expression in adult rat forebrain of mRNA encoding highaffinity neurotensin receptor. J Comp Neurol. 1998; 402(4):475-500.
57. Duvernoy H, Delon S, Vannson JL. The vascularization of the human cerebellar cortex. Brain Res Bull. 1983;11(4):419-480.
58. Ito S, Ohtsuki S, Terasaki T. Functional characterization of the brain-to-blood efflux clearance of human amyloid-β peptide (1-40) across the rat blood-brain barrier. Neurosci Res. 2006;56(3):246-252.
59. Shibata M, et al. Clearance of Alzheimer's amyloidss( 1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest. 2000;106(12):1489-1499.
60. Machida R, Tokumura T, Tsuchiya Y, Sasaki A, Abe K. Pharmacokinetics of novel hexapeptides with neurotensin activity in rats. Biol Pharm Bull. 1993;16(1):43-47.
61. Tokumura T, Tanaka T, Sasaki A, Tsuchiya Y, Abe K, Machida R. Stability of a novel hexapeptide, (Me)Arg-Lys-Pro-Trp-tert-Leu-Leu-OEt, with neurotensin activity, in aqueous solution and in the solid state. Chem Pharm Bull (Tokyo). 1990; 38(11):3094-3098.
62. Sarhan S, Hitchcock JM, Grauffel CA, Wettstein JG. Comparative antipsychotic profiles of neurotensin and a related systemically active peptide agonist. Peptides. 1997;18(8):1223-1227.
63. Orwig KS, Lassetter MR, Hadden MK, Dix TA. Comparison of N-terminal modifications on neurotensin( 8-13) analogues correlates peptide stability but not binding affinity with in vivo efficacy. J Med Chem. 2009;52(7):1803-1813.
64. Tyler-McMahon BM, Stewart JA, Farinas F, McCormick DJ, Richelson E. Highly potent neurotensin analog that causes hypothermia and antinociception. Eur J Pharmacol. 2000;390(1-2):107-111.
65. Buhler AV, Choi J, Proudfit HK, Gebhart GF. Neurotensin activation of the NTR1 on spinallyprojecting serotonergic neurons in the rostral ventromedial medulla is antinociceptive. Pain. 2005; 114(1-2):285-294.
66. Roussy G, et al. Spinal NTS1 receptors regulate nociceptive signaling in a rat formalin tonic pain model. J Neurochem. 2008;105(4):1100-1114.
67. Wustrow DJ, et al. Reduced amine bond neurotenin 8-13 mimettics with potent in vivo activity. Bioorg Med Chem Lett. 1995;5(9):997-1002.
68. Hughes FM Jr, et al. Identification and functional characterization of a stable, centrally active derivative of the neurotensin (8-13) fragment as a potential firstin-class analgesic. J Med Chem. 2010;53(12):4623-4632.
69. Rossi GC, Matulonis JE, Richelson E, Barbut D, Pasternak GW. Systemically and topically active antinociceptive neurotensin compounds. J Pharmacol Exp Ther. 2010;334(3):1075-1079.
70. Tyler BM, et al. In vitro binding and CNS effects of novel neurotensin agonists that cross the blood-brain barrier. Neuropharmacology. 1999; 38(7):1027-1034.
71. Boules M, et al. NT79: A novel neurotensin analog with selective behavioral effects. Brain Res. 2010; 1308:35-46.
72. Bredeloux P, Cavelier F, Dubuc I, Vivet B, Costentin J, Martinez J. Synthesis and biological effects of c(Lys-Lys-Pro-Tyr-Ile-Leu-Lys-Lys-Pro-Tyr- Ile-Leu) (JMV2012), a new analogue of neurotensin that crosses the blood-brain barrier. J Med Chem. 2008; 51(6):1610-1616.
73. Kennedy JD. Neuropathic pain: molecular complexity underlies continuing unmet medical need. J Med Chem. 2007;50(11):2547-2556.
74. Xu B, Descalzi G, Ye HR, Zhuo M, Wang YW. Translational investigation and treatment of neuropathic pain. Mol Pain. 2012;8:15.
75. Buga S, Sarria JE. The management of pain in metastatic bone disease. Cancer Control. 2012; 19(2):154-166.
76. Aapro MS, Coleman RE. Bone health management in patients with breast cancer: current standards and emerging strategies. Breast. 2012;21(1):8-19.
77. Guillemette A, Dansereau MA, Beaudet N, Richelson E, Sarret P. Intrathecal administration of NTS1 agonists reverses nociceptive behaviors in a rat model of neuropathic pain. Eur J Pain. 2012; 16(4):473-484.
78. Tetreault P, et al. Spinal NTS2 receptor activation reverses signs of neuropathic pain. FASEB J. 2013;27(9):3741-3752.
79. Gustavsson A, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011; 21(10):718-779.
80. Weaver AM, Hussaini IM, Mazar A, Henkin J, Gonias SL. Embryonic fibroblasts that are genetically deficient in low density lipoprotein receptor-related protein demonstrate increased activity of the urokinase receptor system and accelerated migration on vitronectin. J Biol Chem. 1997; 272(22):14372-14379.
81. Imber MJ, Pizzo SV. Clearance and binding of two electrophoretic "fast" forms of human α 2-macroglobulin. J Biol Chem. 1981;256(15):8134-8139.
82. Gonias SL, Reynolds JA, Pizzo SV. Physical properties of human alpha 2-macroglobulin following reaction with methylamine and trypsin. Biochim Biophys Acta. 1982;705(3):306-314.
83. LaMarre J, Wolf BB, Kittler EL, Quesenberry PJ, Gonias SL. Regulation of macrophage α 2-macroglobulin receptor/low density lipoprotein receptorrelated protein by lipopolysaccharide and interferon-gamma. J Clin Invest. 1993;91(3):1219-1224.
84. Murza A, et al. Elucidation of the structure-activity relationships of apelin: influence of unnatural amino acids on binding, signaling, and plasma stability. Chem Med Chem. 2012;7(2):318-325.
85. Breton B, Sauvageau E, Zhou J, Bonin H, Le Gouill C, Bouvier M. Multiplexing of multicolor bioluminescence resonance energy transfer. Biophys J. 2010; 99(12):4037-4046.
86. Richard-Lalonde M, et al. Conformational dynamics of Kir3.1/Kir3.2 channel activation via δ-opioid receptors. Mol Pharmacol. 2013;83(2):416-428.
87. Koole C, et al. Allosteric ligands of the glucagonlike peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. Mol Pharmacol. 2010; 78(3):456-465.
88. Dagenais C, Rousselle C, Pollack GM, Scherrmann JM. Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice. J Cereb Blood Flow Metab. 2000;20(2):381-386.
89. Dubuisson D, Dennis SG. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain. 1977;4(2):161-174.
90. Coderre TJ, Fundytus ME, McKenna JE, Dalal S, Melzack R. The formalin test: a validation of the weighted-scores method of behavioural pain rating. Pain. 1993;54(1):43-50.
91. Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain. 1988;33(1):87-107.